MARKET

FBIO

FBIO

Fortress Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.461
+0.011
+0.32%
Opening 14:07 01/22 EST
OPEN
3.400
PREV CLOSE
3.450
HIGH
3.560
LOW
3.400
VOLUME
389.03K
TURNOVER
--
52 WEEK HIGH
4.780
52 WEEK LOW
1.040
MARKET CAP
324.31M
P/E (TTM)
-4.0574
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment and Drugs Market to Witness a Notable CAGR During 2021-2029; Growing Number of Head and Neck Cancer Cases to Create Opportunities for Market Growth
Jan 18, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment and Drugs Market: Global...
AmericaNewsHour · 4d ago
When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Fortress Biotech, Inc.'s...
Simply Wall St. · 6d ago
Immune Checkpoint Inhibitors Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Jan 15, 2021 (Market Insight Reports) -- The Global Immune Checkpoint Inhibitors Market is estimated to value over USD 26 billion by 2027 end with a CAGR of...
Market Insight Reports · 01/15 10:06
Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences
Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021.
GlobeNewswire · 01/06 13:33
Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will particip...
GlobeNewswire · 01/06 13:30
Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologi...
GlobeNewswire · 01/05 13:30
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13R2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
Trial underway at City of Hope to evaluate safety and feasibility of administering therapy in patients with brain tumors such as glioblastoma, ependymoma or medulloblastomaWORCESTER, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (N...
GlobeNewswire · 12/21/2020 13:00
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that a Phase 1 single-center, two-arm clinical trial has been initiated to establish the safety and feasibility of administering MB-101 (autologous IL13Rα2-CAR T cells) to patients with leptomeningeal brain tumors (e.g., glioblastoma, ependymoma or medulloblastoma). The trial will enroll up to 30 patients and take place at City of Hope, where the chimeric antigen receptor T ("CAR T") cell therapy was initially developed.
GlobeNewswire · 12/21/2020 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FBIO. Analyze the recent business situations of Fortress Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FBIO stock price target is 8.92 with a high estimate of 16.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 31.95M
% Owned: 34.10%
Shares Outstanding: 93.70M
TypeInstitutionsShares
Increased
30
8.30M
New
24
600.56K
Decreased
14
681.58K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.79%
Pharmaceuticals & Medical Research
+0.75%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Lindsay Rosenwald
Vice Chairman/Director
Eric Rowinsky
Chief Financial Officer/Treasurer/Secretary
Robyn Hunter
Corporate Executive/Executive Director
Michael Weiss
Senior Vice President
George Avgerinos
Independent Director
Jimmie Harvey
Independent Director
Malcolm Hoenlein
Independent Director
Dov Klein
Independent Director
J. Jay Lobell
Independent Director
Kevin Lorenz
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FBIO
Fortress Biotech, Inc.(Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.
More

Webull offers kinds of Fortress Biotech Inc stock information, including NASDAQ:FBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FBIO stock methods without spending real money on the virtual paper trading platform.